GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (NAS:NXTC) » Definitions » FCF Yield %

NXTC (NextCure) FCF Yield % : -147.49 (As of Dec. 13, 2024)


View and export this data going back to 2019. Start your Free Trial

What is NextCure FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, NextCure's Trailing 12-Month Free Cash Flow is $-45.03 Mil, and Market Cap is $30.53 Mil. Therefore, NextCure's FCF Yield % for today is -147.49%.

The historical rank and industry rank for NextCure's FCF Yield % or its related term are showing as below:

NXTC' s FCF Yield % Range Over the Past 10 Years
Min: -177.48   Med: -36.85   Max: 0.68
Current: -147.49


During the past 7 years, the highest FCF Yield % of NextCure was 0.68%. The lowest was -177.48%. And the median was -36.85%.

NXTC's FCF Yield % is ranked worse than
89.58% of 1507 companies
in the Biotechnology industry
Industry Median: -13.02 vs NXTC: -147.49

NextCure's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.


NextCure FCF Yield % Historical Data

The historical data trend for NextCure's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCure FCF Yield % Chart

NextCure Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial -2.52 -17.33 -35.91 -143.00 -169.11

NextCure Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -145.43 -134.34 -81.27 -90.62 -121.31

Competitive Comparison of NextCure's FCF Yield %

For the Biotechnology subindustry, NextCure's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NextCure's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCure's FCF Yield % distribution charts can be found below:

* The bar in red indicates where NextCure's FCF Yield % falls into.



NextCure FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

NextCure's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-53.794 / 31.80942
=-169.11%

NextCure's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-11.624 * 4 / 38.326846
=-121.31%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NextCure FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


NextCure FCF Yield % Related Terms

Thank you for viewing the detailed overview of NextCure's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


NextCure Business Description

Traded in Other Exchanges
Address
9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
Executives
Anne Elizabeth Borgman director 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Ellen Feigal director C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Kevin G. Shaw officer: Sr VP, Legal Affairs 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Sourav Kundu officer: Sr VP, Dev. & Mfg. 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Han Myint officer: Chief Medical Officer C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Timothy Mayer officer: Chief Operating Officer C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Sol Langermann officer: Chief Scientific Officer C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Steven P. Cobourn officer: Chief Financial Officer C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Linda Liu officer: SVP, Research C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Michael Richman director, officer: President & CEO 2635 TECHNOLOGY FOREST BLVD., HOUSTON TX 77381
John G Houston director C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Garry A Nicholson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Anand Mehra 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Michael Powell 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
James Healy 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025